

CNV detection

from targeted next-generation sequencing data

Anna Benet-Pagès

Johor 29.08.2018

Detection of structural variants and human disease



B/B⁺

Calvin Bridges, 1936






FIGURE 1B: G-banding karyotype of 46, XY individual.


G-banding Rowley et al., 1973




FISH Langer et al., 1982




Quantitative PCR Porcher et al., 1992



Array CGH Pinkel et al., 1998c



MLPA Schouten et al., 2002




SNP array Komura et al., 2006




High resolution technologies reveal small-size CNVs

Size distribution of copy number variations (CNVs) larger than 100 bp




Zhang et al. 2009



- Smaller structural variants are the most frequent

On the meanwhile...



CNV detection from targeted-capture data

Challenges:


- CNV detection from exon capture approaches depends solely on read depth data
- Enrichment efficiency introduces a systematic noise in read depth data
- Coverage bias between sequencing runs and within samples of the same run
- Single exon events are extremely difficult to detect
- Control individuals are difficult to obtain (reference set / validation)
- Validation is expensive

CNV detection methods general considerations



➤ Which tool should I choose?

- applicable to capture data
- calling of rare CNVs
- easy to integrate (take bam files as input)
- easy handling (installation / running time)
- multi-sample usage (possibility to normalize against reference set)
- Tools should use different statistic models


CNV Pipeline Structure



breakdown of the target
region exons/ windows




GC
Mapping qual
reads
Ref. Set



Reference Sets and data normalization

- different reference sets for different kits / enrichment methods
- normalization against samples from the same sequencing run to improve robustness against workflow conditions


illumina



SMARCB1 - Exons




Agilent



SMARCB1 - Exons




CNV Pipeline Structure




Poisson distribution
Beta binomial
Negative binomial
Normal distribution


Coverage	frequency
50	24
100	95
200	82
500	21



CNV Pipeline Structure



grouping areas (exon/window) with the same prediction (gain / loss / normal)



CNV detection methods

- Use a combination of several detection tools

AGE, BicSeq, BreakDancer, Breakpointer, Breakseq, Canoes, Clamms, Clever, ClipCrop, Cn.MOPS, CNAnorm, CNAseq, CND, CNV_TV, Cnvator, CNVer, CNVer, HugeSEQ, hydra, inGAP_sv, JointS **„meta-CNV-caller“** rcanavar, Patchwork, pmer, ReadDepth, rSW_seq, segseq, seqcbs, CNVer, cnvHiTSeq, cnvrd, CNV-seq, conserting, CONTROL_FREEEC, cops, copySeq, crest, ERDS, codex EWT_RDXplorer, GasvPRO, GENSENG, XHMM

Meta-Tool CNV Detection Pipeline

- **ExomeDepth**

extremely sensitive and robust against samples that do not correlate with the reference

- **Canoes**

has a high sensitivity for small deletions, high performance in low coverage regions and with few reference samples

- **Clamms**

corrects for GC content and mappability, divides large exons into smaller regions and calls also common CNVs

- **Codex**

corrects for GC content and mappability, calls also common CNVs, uses no HMM for segmentation (all other tools use HMMs)

- **Inhouse method**

is well adapted on inhouse data, screens for heterozygosity, corrects for GC content, exon score depends on previous analyses


Performance of single tools

- Training set: true set of 146 CNV calls detected via MLPA.


	Exome Depth	Clamms	Canoes	Codex	In-house
Precision	45.63%	68.57%	96.77%	64.75%	40.82%
Sensitivity	90.38%	46.15%	57.69%	63.46%	76.92%

Performance of tool combinations

- What is the best number of tools required to call a variant?


 stringency		TP	FN	FP	TN	Sensitivity (TPR)	Specificity (TNR)	Precision (PPV)	NPV
	2 out of 5	115	7	8	3600	94.26%	99.78%	93.50%	99.81%
	3 out of 5	72	50	1	3600	59.02%	99.97%	98.63%	98.63%
	4 out of 5	28	94	1	3600	22.95%	99.97%	96.55%	97.46%
	5 out of 5	4	118	0	3600	3.28%	100.00%	100.00%	96.83%

- Using two out of five concordant tool predictions shows the best balance between sensitivity and specificity



CNV Pipeline Evaluation

- >3700 MLPAs were performed in ~90 genes
- 146 CNVs (85 deletions / 61 gains)




Sensitivity: 88.60%
Specificity: 98.88%
Precision: 71.40%

Pseudogenes excluded:

Sensitivity: 94.26%
Specificity: 99.78%
Precision: 93.50%

TP, FP , FN versus CNV size


- Comparison of CNV sizes of TP, FP and FN calls detected by the combined CNV pipeline on the validation set.
- FP mainly consist and FN calls consist mainly of single exon events.




definition of special quality thresholds for single exon events to minimize false negatives

Discrepancies in CNV size detection between tools

- Size of CNV calls were compared to MLPA
- Size is given as the number of exons within the call



Meta-CNV-caller: multi calls for one event



Copy Number Variants in NBN

Calls 2


	Exons	Type	CN	Sample	Pool	Region	PPL	Overlap (min)	Overlap (equal)	Overlap (ExAC)	Overlap (Pool)	Methods
1	E2 – E12	+	3	121258	SP-666	chr8: 90,955,481 - 90,996,789		1		9		clams CN3, exomedepth CN3
2	E3 – E15	+	3	121258	SP-666	chr8: 90,947,810 - 90,995,083		1		9		canoes CN3, exomedepth CN3

Challenges

- ❖ Non-uniform of coverage
- ❖ CNV calling in homologous genomic regions (pseudogenes...)
- ❖ Clinical interpretation

non-uniform coverage = capture bias

- identification of reliable regions by assessment of capture efficiency to minimize false positives




can not be analyzed

CNV calling artifacts

2. SCN1A

Number of exons 26
Duplications in 5 exons and 4 calls (frequency = 0.00)
Deletions in 26 exons and 39 calls (frequency = 0.01)

- Depth of coverage uniformity reference set
- Depth of coverage uniformity sample



CNV calling in Pseudogenes

- Forward read / unique mapping
- Reverse read / unique mapping
- Non-unique mapping


1. PMS2



PMS2 exons 11 – 15 can not be analyzed

CNV calling in Pseudogenes

PMS2




PMS2CL



How to identify regions affected by pseudogenes

- alignments of the human genome with itself using blastz



Home
Human
Mouse
Mouse Strains
psiCube
PseudoFam
PseudoPipe
Archive
FAQ
About

Human Pseudogene Annotation

GENCODE Annotation

- **Data:** The current human manual annotation is available from GENCODE. [↗](#)

- **Description:** The GENCODE annotation of pseudogenes contains models that have been created by the Human and Vertebrate Analysis and Annotation (HAVANA) team, an expert manual annotation team at the Wellcome Trust Sanger Institute. This is informed by, and checked against, computational pseudogene predictions by the [PseudoPipe](#) and [RetroFinder](#) pipelines.

PseudoPipe Output

- **Data:** The current PseudoPipe results are on Ensembl genome release 90. [↗](#)

- **Description:** Genome-wide human pseudogene annotation predicted by PseudoPipe. PseudoPipe is a homology-based computational pipeline that searches a mammalian genome and identifies pseudogene sequences.

- **Reference:** [↗](#)

Other Human Pseudogene Sets

- **Data:** [↗](#)

- **Description:** Archived pseudogene annotation on previous human genome releases from PseudoPipe. Genome-wide annotation or specific subset.

Interpretation of CNV calls – population DB

- Deletions and duplications called based on read depth usingXHMM; *Fromer et al.*
- Z score for the deviation of observed counts from the expected number



Positive Z scores indicate that the gene had fewer variants than expected.
Negative Z scores are given to genes that had a more variants than expected.

Interpretation of CNV calls – clinical DB

- DGV
- DECIPHER
- ClinVar
- ClinGen



ClinGen Dosage Sensitivity Curation Page

FBN1

Curation Status: Complete

id: ISCA-30689

Date last evaluated: 2014-06-04

Issue Type: ClinGen Gene Curation

Gene type: protein-coding

Entrez Gene: <https://www.ncbi.nlm.nih.gov/gene/2200>

OMIM: <https://omim.org/entry/134797>

Gene Reviews: <https://www.ncbi.nlm.nih.gov/books/NBK1116/?term=FBN1%5Bgenesymbol%5D>

ClinGen Haploinsufficiency Score: [3](#)

ClinGen Triplosensitivity Score: [0](#)

[ExAC pLI score](#): 1.0

Location Information

15q21.1

GRCh37/hg19 chr15: 48,700,503-48,937,985

View: [NCBI](#) | [Ensembl](#) | [UCSC](#)

GRCh38/hg38 chr15: 48,408,306-48,645,788

View: [NCBI](#) | [Ensembl](#) | [UCSC](#)

Links

[ClinGen Curation Home Page](#)

[ClinGen Home Page](#)

[Help with this site](#)

[FAQ](#)

[Contact Us](#)

[Pathogenic regions \(nstd45\)](#)

[Curation of the ACMG 59 Genes](#)

[FTP](#)

[Report information on a gene](#)

[Print Full Report](#)

Genome View

Evidence for Haploinsufficiency Phenotypes

Evidence for Triplosensitive Phenotypes

Haploinsufficiency score: 3

Strength of Evidence (disclaimer): Sufficient evidence for dosage pathogenicity

Haploinsufficiency Phenotype: [MARFAN SYNDROME; MFS](#)

Evidence for haploinsufficiency phenotype

PubMed ID	Description
17701892	Faivre et al. (2007) report on 1,013 patients with Marfan Syndrome and a pathogenic FBN1 mutation as part of the Universal Mutation Database for FBN1. There are 170 frameshift mutations and 137 nonsense mutations in this group.
8406497	Dietz et al. (1993) identified an 83 bp deletion in FBN1 resulting in a premature stop codon in a patient with Marfan syndrome.
21063442	Hilhorst-Hofstee et al. (2011) report a family with a focal deletion of FBN1 where all deletion carriers meet Ghent criteria for Marfan syndrome. Additional patients with larger deletion which include additional genes are described who meet clinical criteria for Marfan syndrome.


Interpretation of CNV calls – clinical DB



ClinGen Dosage Sensitivity Curation Page

Links

[ClinGen Curation Home Page](#)
[ClinGen Home Page](#)
[Help with this site](#)
[FAQ](#)
[Contact Us](#)
[Pathogenic regions \(nstd45\)](#)
[Curation of the ACMG 59 Genes](#)
[FTP](#)
[Report information on a gene](#)



[Print Full Report](#)

[17701892](#)

Faivre et al. (2007) report on 1,013 patients with Marfan Syndrome and a pathogenic FBN1 mutation as part of the Universal Mutation Database for FBN1. There are 170 frameshift mutations and 137 nonsense mutations in this group.

[8406497](#)

Dietz et al. (1993) identified an 83 bp deletion in FBN1 resulting in a premature stop codon in a patient with Marfan syndrome.


[21063442](#)

Hilhorst-Hofstee et al. (2011) report a family with a focal deletion of FBN1 where all deletion carriers meet Ghent criteria for Marfan syndrome. Additional patients with larger deletion which include additional genes are described who meet clinical criteria for Marfan syndrome.

CNV analysis on **1600** individuals within the routine Dx

CNV clarified the underlying phenotype in 8 % of the cases

**Increase of the
diagnostic yield in 3%**



benet-pages@mgz-muenchen.de

